Oxycodone in Treatment of Early Labour Pain Efficacy and Safety
NCT ID: NCT02575677
Last Updated: 2023-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2012-10-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Oxycodone to the Placental Circulation at Early Labour
NCT02573831
Oxycodone for Labor Pain - Pharmacokinetics (PK), Safety and Efficacy
NCT01016821
The Experience of Giving Birth With Remifentanil for Pain Relief: A Qualitative Study of Mothers and Midwives
NCT07030777
Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation
NCT02487797
VPIA Remifentanil for Labour Pain to Reduce Maternal Desaturation and Improve Analgesic Titration
NCT02733835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parturients with oxycodone
Parturients who were given oxycodone
oxycodone
oxycodone 0,1/kg up to 10 mg sc.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oxycodone
oxycodone 0,1/kg up to 10 mg sc.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18 years or more
* given informed consent
Exclusion Criteria
* age less than 18 years
* no informed consent
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Admescope Ltd
INDUSTRY
Kuopio University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Merja Kokki
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merja Kokki, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Kuopio University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kuopio University Hospital
Kuopio, Northern Savonia, Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Merja Kokki, PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Merja Kokki, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUH26062012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.